Literature DB >> 28070010

Low Level of Hepatitis B Virus Infection in Children 20 Years After Initiation of Infant Vaccination Program in Wallis and Futuna.

Lorenzo Pezzoli1, Jean Pierre Mathelin2, Karen Hennessey3, Padmasiri Eswara-Aratchige4, Jayaprakash Valiakolleri4, Sung Hye Kim4.   

Abstract

The prevalence of hepatitis B virus (HBV) in Wallis and Futuna (WAF) was one of the highest in the Pacific and was the driving factor for introducing hepatitis B (HepB) vaccination in 1992 and HepB birth dose (HepB-BD) in 2006. Using lymphatic filariasis (LF) transmission assessment survey (TAS) as a survey platform for eliminating LF, we assessed HBV surface antigen (HBsAg) seroprevalence, HepB vaccination coverage, and its timeliness among schoolchildren in WAF. From one finger prick of all registered fourth and fifth grade students, we tested HBsAg and filariasis antigen simultaneously, and estimated HepB vaccination coverage and timeliness by reviewing students' immunization cards. Since the children targeted were born when the three-dose HepB schedule was 2, 3, and 8 months, we defined timely vaccination if each dose was given by 3, 4, and 12 months. Of 476 targeted, 427 were enrolled. HBsAg prevalence was 0.9%. Estimated HepB vaccination coverage was 97%, 97%, and 96% for the first, second, and third doses, respectively, yielding coverage for all three doses of 96%. Proportion of timely vaccination was lower: 80%, 56%, and 65%, respectively, and less than 50% for all three doses combined. The seroprevalence of HBsAg among schoolchildren in WAF is less than 1%, close to the control goal. HepB vaccination coverage was high, but many children were vaccinated late. We recommend increasing the efforts for timely HepB vaccination. By combining an HBV seroprevalence survey and coverage assessment, we demonstrated the benefit of using TAS as a public health platform to access schoolchildren.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28070010      PMCID: PMC5361551          DOI: 10.4269/ajtmh.16-0596

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

Review 1.  Epidemiology of hepatitis B in Europe and worldwide.

Authors:  Miriam J Alter
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  [Hepatitis B in Wallis: results of a seroepidemiological survey].

Authors:  F J Louis; M Morillon; B Boye; B Soullie; M Huerre; R Labrouasse; C Sapin; M Amouretti
Journal:  Bull Soc Pathol Exot       Date:  1992

3.  The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu.

Authors:  N Wilson; T A Ruff; B J Rana; J Leydon; S Locarnini
Journal:  Vaccine       Date:  2000-07-01       Impact factor: 3.641

4.  Hepatitis B vaccination in children: the Taiwan experience.

Authors:  Y-H Ni; D-S Chen
Journal:  Pathol Biol (Paris)       Date:  2010-01-29

5.  Prevalence of antibody to hepatitis A and hepatitis B viruses in selected populations of the South Pacific.

Authors:  D C Wong; R H Purcell; L Rosen
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

Review 6.  Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period.

Authors:  Zhuanbo Luo; Lanjuan Li; Bing Ruan
Journal:  Int J Infect Dis       Date:  2011-12-17       Impact factor: 3.623

7.  Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications.

Authors:  Manju Rani; Baoping Yang; Richard Nesbit
Journal:  Bull World Health Organ       Date:  2009-09       Impact factor: 9.408

Review 8.  Risks of chronicity following acute hepatitis B virus infection: a review.

Authors:  K C Hyams
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

9.  Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France.

Authors:  Julie Bottero; Anders Boyd; Joel Gozlan; Maud Lemoine; Fabrice Carrat; Anne Collignon; Nicolas Boo; Philippe Dhotte; Brigitte Varsat; Gérard Muller; Olivier Cha; Odile Picard; Jean Nau; Pauline Campa; Benjamin Silbermann; Marc Bary; Pierre-Marie Girard; Karine Lacombe
Journal:  J Hepatol       Date:  2012-11-23       Impact factor: 25.083

10.  The necessity of booster vaccination after neonatal hepatitis B vaccination.

Authors:  Kamran Bagheri Lankarani
Journal:  Hepat Mon       Date:  2011-06       Impact factor: 0.660

View more
  1 in total

1.  Vaccination timeliness and delay in low- and middle-income countries: a systematic review of the literature, 2007-2017.

Authors:  Nina B Masters; Abram L Wagner; Matthew L Boulton
Journal:  Hum Vaccin Immunother       Date:  2019-06-12       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.